News | August 07, 2024
Gland Pharma posts 16% revenue growth in Q1 FY25
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
Reported profit after tax declined 19% year-on-year to Rs 76 crores
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
Launch of 20 new medicines expected by 2030
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
2024 full-year revenue guidance raised by US$ 2 billion
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
International Business is expected to register double-digit growth in constant currency terms
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Subscribe To Our Newsletter & Stay Updated
